CAPTODIAME

First approved in 1958

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H29NS2
Molecular Weight	359.592
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCSC1=CC=C(C=C1)C(SCCN(C)C)C2=CC=CC=C2

InChI

InChIKey=IZLPZXSZLLELBJ-UHFFFAOYSA-N

InChI=1S/C21H29NS2/c1-4-5-16-23-20-13-11-19(12-14-20)21(24-17-15-22(2)3)18-9-7-6-8-10-18/h6-14,21H,4-5,15-17H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C21H29NS2
Molecular Weight	359.592
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23863923 | https://www.ncbi.nlm.nih.gov/pubmed/15383182

CAPTODIAME, also known as captodiamine, is a diphenylmethane derivative. It is a 5-HT2c receptor antagonist and agonist at sigma-1 and D3 dopamine receptors. It is an antihistamine which is used as a sedative and anxiolytic. CAPTODIAME is probably useful in preventing benzodiazepine withdrawal syndrome.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
anxiety 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14431646	Primary		Approved 8429	Suvren Approved Use Unknown

Doses

Dose	Population	Adverse events
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15383182 Page: p.1349	unhealthy, 25 - 55 n = 40 Health Status: unhealthy Condition: Benzodiazepine withdrawal syndrome Age Group: 25 - 55 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/15383182 Page: p.1349	Sources: https://pubmed.ncbi.nlm.nih.gov/15383182 Page: p.1349

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY556403	https://www.001chemical.com/chem/486-17-9
ABI Chem	AC1L1US5
Alfa Chemistry	ACM904041
Aurora Fine Chemicals LLC	A17.944.752	http://online.aurorafinechemicals.com/info?ID=A17.944.752
BLD Pharm	BD119883	http://www.bldpharm.com/products/486-17-9.html
BOC Sciences	486-17-9
ChemMol	99090838	http://www.chemmol.com/chemmol/99090838.html
Chemieliva Pharmaceutical Co., Ltd	PBCM1315640
Compound Cloud	10240
Molcore	MC556403	https://www.molcore.com/product/486-17-9
NovoSeek	10240
Sigma Aldrich	PH003219
Sigma Aldrich	PH003219\|ALDRICH
Sigma-Aldrich	PH003219_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph003219
Smolecule	S522615	http://www.smolecule.com/products/s522615
THE BioTek	bt-262702	https://www.thebiotek.com/product/inhibitors/bt-262702
ZINC	ZINC000002040210	http://zinc15.docking.org/substances/ZINC000002040210
ZINC	ZINC000002040211	http://zinc15.docking.org/substances/ZINC000002040211

PubMed

Title	Date	PubMed
Captodiame in anxiety states in general practice.	1960 Aug	14431646
The role of captodiamine in the withdrawal from long-term benzodiazepine treatment.	2004 Sep	15383182
Captodiamine, a putative antidepressant, enhances hypothalamic BDNF expression in vivo by synergistic 5-HT2c receptor antagonism and sigma-1 receptor agonism.	2013 Oct	23863923

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:30:52 GMT 2023` Edited by `admin` on `Fri Dec 15 16:30:52 GMT 2023`
Record UNII	H93K9455DD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CAPTODIAME

Official Name

English

ETHYLAMINE, 2-((P-(BUTYLTHIO)-.ALPHA.-PHENYLBENZYL)THIO)-N,N-DIMETHYL-

Common Name

English

CAPTODIAMINE [MI]

Common Name

English

Captodiame [WHO-DD]

Common Name

English

P-BUTYLTHIODIPHENYLMETHYL 2-DIMETHYLAMINOETHYL SULPHIDE

Common Name

English

CAPTODIAMINE

Common Name

English

BUTYLTHIODIPHENYLMETHYL 2-DIMETHYLAMINOETHYL SULFIDE

Systematic Name

English

2-(P-(BUTYLTHIO)-.ALPHA.-PHENYLBENZYLTHIO)-N,N-DIMETHYLETHYLAMINE

Common Name

English

P-BUTYLTHIODIPHENYLMETHYL 2-DIMETHYLAMINOETHYL SULFIDE

Common Name

English

captodiame [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN05BB02